FDA finds Amgen biosimilar replicates effects of Humira
The Food and Drug Administration said a new Amgen biosimilar replicates the effects of a competitor’s blockbuster drug July 8. ABP 501 replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and colon inflammation. The drug, made by Chicago-based competitor AbbVie, typically costs $20,000 per year for Read More →
Health care nonprofits merge to expand Ventura County service
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Santa Barbara home health care service lifeline for seniors
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Stellar Biotechnologies offerings raise $6.75 million
Stellar Biotechnologies, a Port Hueneme-based company which makes medicines from the blood of animals found only off the coast of California, closed two private offerings July 6. Stellar closed one offering of 1.7 million common shares sold to institutional investors for $4 per share. In a separate concurrent offering, the company also sold 1.3 million Read More →
Europeans OK Amgen’s Kyprolis for multiple myeloma treatment
European regulators approved Amgen’s potential blockbuster drug Kyprolis on July 4 as a treatment for multiple myeloma. The European Commission approved a treatment of Kyprolis and dexamethasone in patients who’ve received at least one previous multiple myeloma treatment. In November, the commission approved a Kyprolis treatment using lenalidomide and dexamethasone for patients who’ve received at Read More →
Stellar Biotechnologies uses limpets to develop medicine
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s new drug for migraines shows promise
Thousand Oaks-based Amgen said a drug being developed in collaboration with Novartis showed promising results in providing relief for patients suffering from chronic migraines. The Phase 2 clinical trial met benchmarks for migraine reduction at two levels of dosage and with limited side effects. “Migraine is the sixth-leading cause of disability worldwide. Three to seven Read More →
